Recent data suggests that clinical trials using biomarkers – including genomic biomarkers – are twice as likely to succeed versus those that don’t.1 According to a 2018 analysis, The Innovation Imperative: The Future of Drug Development, by the Economist Intelligence Unit (EIU) and commissioned by Parexel, drugs developed using innovative trial methods, including precision medicine trial designs, are adopted by payers more quickly.2 In short, payers want to know which patients are more likely to avoid making reimbursements for ineffective treatments.